Controversies in the treatment of breast cancer with CDK4/CDK6 inhibitors
The ebb and flow of adjuvant trials
0 COMENTÁRIOSThe ebb and flow of adjuvant trials
0 COMENTÁRIOSInterim analysis of the CheckMate 577 study
1 COMENTÁRIOSInhibition of CDK-4 / CDK-6
1 COMENTÁRIOSHer-2 dual blockade strategy in the curative treatment of early breast cancer
2 COMENTÁRIOS